Grail, Inc.(GRAL)
Search documents
Grail, Inc.(GRAL) - 2024 Q2 - Quarterly Report
2024-08-13 20:59
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |----------------------------------------------- ...
Grail, Inc.(GRAL) - 2024 Q2 - Quarterly Results
2024-08-13 20:15
NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif. — Aug. 13, 2024 — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2024. Revenue in the second quarter was ...